MedTrace Logo

Pilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication

NCT02486289 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2021-03-08

No results posted yet for this study

Summary

A randomized, placebo controlled, double blind proof of concept study of NBMI in treatment of mercury intoxication.

Conditions

  • Mercury Poisoning

Interventions

DRUG

Emeramide

Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)

DRUG

Placebo

NBMI Placebo

Sponsors & Collaborators

  • NBMI Science AB

    collaborator UNKNOWN

  • EmeraMed

    lead INDUSTRY

Principal Investigators

  • Augusto Focil Baquerizo, MD · FOMAT Medical Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-01-31
Completion
2016-04-30

Countries

  • Ecuador

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02486289 on ClinicalTrials.gov